What is Innerwell?
Innerwell operates as a specialized healthtech platform providing at-home psychedelic therapy, integrated with personalized guidance from licensed clinicians. The company addresses a critical gap in the mental health sector by combining traditional psychiatric care with innovative treatments such as ketamine-assisted therapy and EMDR. By leveraging a digital-first approach, Innerwell offers a scalable solution for individuals suffering from depression, anxiety, and PTSD. Their model emphasizes a personalized treatment protocol, ensuring that patients receive evidence-based care tailored to their specific clinical needs, thereby improving long-term mental health outcomes in a highly fragmented industry.
How much funding has Innerwell raised?
Innerwell has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2022): $3M with participation from Looking Glass, Greycroft Partners, and Max-Ventures
Key Investors in Innerwell
Greycroft Partners
Greycroft is a leading venture capital firm focused on investments in the Internet and mobile markets, leveraging an extensive network to help entrepreneurs build successful businesses.
Max-Ventures
Max-Ventures is a firm operating within the Venture Capital and Private Equity industry, providing strategic support to growing enterprises.
Looking Glass
Undisclosed investor participating in the funding round.
What's next for Innerwell?
With the support of its latest financing, Innerwell is poised to accelerate its growth trajectory by broadening its geographic footprint and deepening its clinical capabilities. The company is expected to focus on optimizing its patient acquisition strategies and enhancing its digital platform to support a higher volume of therapeutic sessions. Furthermore, the strategic backing from institutional investors suggests a focus on long-term sustainability and potential integration into broader healthcare ecosystems. As Innerwell continues to refine its evidence-based protocols, the firm is well-positioned to lead the shift toward more accessible, technology-enabled mental health interventions, potentially setting new standards for the delivery of psychedelic-assisted care in a regulated, enterprise-grade environment.
See full Innerwell company page
